SITC 2017 Abstract Titles – Cancer Vaccines

To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.







CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against GBM

Catalina Soare1, Tanvir Ahmed1, Julie Joseph1, Anne-Catherine Fluckiger1, Barthelemy Ontsouka1, Abebaw Diress1, Jasminka Bozic1, Marc Kirchmeier1, Francisco Diaz-Mitoma1, David E Anderson1

1VBI Vaccines, Cambridge, MA, USA

Antigen presenting cells | Tumor antigens | T cell | Vaccine


Induction of folate receptor alpha-specific Th17 T cell immunity in ovarian cancer patients

Matthew Block1, Kimberly Kalli1, Jacob Allred1, Courtney Erskine1, Allan Dietz1, Michael Gustafson1, Yi Lin1, Keith Knutson2, Martin Cannon3

1Mayo Clinic, Rochester, MN, USA 2Mayo Clinic, Jacksonville, FL, USA 3University of Arkansas for Medical Sciences, Little Rock, AR, USA

Vaccine | Dendritic cell | Immune monitoring | Tumor antigens | Antibody | T cell | Solid tumors | Cytokine | Clinical trial


Anti-NY-ESO-1 Immune Response and Survival Benefit After LV305 Therapy in Patients With Advanced Sarcoma and Other Solid Tumors

Neeta Somaiah1, Matthew Block2, Joseph W. Kim3, Geoffrey Shapiro4, Khanh Tu Do4, Patrick Hwu1, Joseph Paul Eder3, Robin Lewis Jones5, Sacha Gnjatic6, Hailing Lu7, Jan H. ter Meulen7, Michael Chen9, Chet Bohac8, Frank Hsu8, Seth Pollack10

1MD Anderson Cancer Center, Houston, TX, USA 2Mayo Clinic, Rochester, MN, USA 3Yale University, New Haven, CT, USA 4Dana Farber Cancer Institute, Brookline, MA, USA 5Royal Marsden NHS, London, United Kingdom 6Tisch Cancer Institute, New York, CA, USA 7Immune Design, Seattle, WA, USA 8Immune Design, South San Francisco, CA, USA 9Biostatistics, South San Francisco, CA, USA 10Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Dendritic cell | Biomarkers | Clinical trial | Vaccine | Solid tumors | Tumor antigens


MEK inhibition augments Talimogene laherparepvec (T-VEC)-mediated in vitromelanoma oncolysis and induces in vivo tumor regression

Howard Kaufman1, Praveen Bommareddy1, Anne Silk1, Andrew Zloza1, Sachin Jhawar1

1Rutgers University, New Brunswick, NJ, USA

Tumor microenvironment | Vaccine | Solid tumors


Initial Safety and Production Efficiency of an Autologous Tumor Lysate-Loaded Yeast Cell Wall Particle Vaccine

Tommy Brown1, Kaitlin Peace1, Myers John1, Timothy Vreeland2, Diane Hale1, Doreen Jackson1, Julia Green1, Jamie Berry3, Clifton Guy1, Herbert Garth1, Xianzhong Yu4, Thomas Wagner5, George Peoples6

1Brooke Army Medical Center, San Antonio, TX, USA 2University of Texas MD Anderson Cancer Center, Houston, TX, USA 3Womack Army Medical Center, Fort Bragg, NC, USA 4Clemson University, Clemson, SC, USA 5Orbis Health Solutions, Greenville, SC, USA 6Metis Foundation, San Antonio, TX, USA

Vaccine | Solid tumors | Dendritic cell | Tumor antigens | Targeted therapy | Clinical trial | Antigen presenting cells | T cell | Monocyte/Macrophage | Immune adjuvant


Telomerase peptide vaccine treatment of patients with locally advanced or metastatic non-small cell lung cancer: Report from a phase I/IIA trial

Tormod Kyrre Guren1, Else Marit Inderberg2, Paal Fr. Brunsvig1, Odd Terje Brustugun3, Jon Amund Kyte1, Jens Bjørheim4, Wenche Rasch4, Claudius H. Reisse1, Gustav Gaudernack4, Steinar Aamdal1

1Oslo University Hospital, Oslo, Norway 2University of Oslo, Oslo, Norway 3Vestre Viken Hospital Trust, Drammen, Norway 4Ultimovacs AS, Oslo, Norway

Clinical trial | Vaccine | Immune monitoring | Clinical study | Solid tumors


OncoPept VAC: A robust TCR binding algorithm to prioritize neoepitope using tumor mutation (DNAseq) and gene expression (RNAseq) data

Papia Chakraborty1, Amit Chaudhuri1, Vasumathi Kode1, Snigdha Majumdar1, Priyanka Shah1, Malini Manoharan1, Ravi Gupta1

1MedGenome Inc, Foster City, CA, USA

Neoantigens | Adoptive immunotherapy | T cell | Vaccine


No toxicity and long-term survival up to 16-years from repeated oncolytic vaccine systemic immunotherapy in advanced melanoma: Teaching us lessons.

Brendon Coventry1, Carrie Lilly1, Tony Michele2, Peter Hersey3

1University of Adelaide, Adelaide, Australia 2Adelaide Oncology & Haematology, North Adelaide, South Australia, Australia 3University of Sydney, Sydney, Australia

Clinical study | Clinical trial | Immune toxicity | Vaccine | Solid tumors | Immune adjuvant


Inflammatory Response After Immunotherapy with a Yeast-CEA Therapeutic Cancer Vaccine in Metastatic Medullary Thyroid Cancer

Jaydira Del Rivero1, Ann Gramza2, Myrna Rausckhorts1, Marijo Bilusic1, Fatima Karzai1, Julius Strauss1, Lisa Cordes1, William L. Dahut1, Jeffrey Schlom1, James L. Gulley1, Ravi A. Madan1

1National Cancer Institute/National Institutes of Health, Bethesda, MD, USA 2Medstar Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA

Inflammation | Tumor microenvironment | Vaccine | Clinical trial | Clinical study


Heat-inactivated modified vaccinia virus Ankara (MVA) as vaccine adjuvant

Ning Yang1, Stewart Shuman1, Taha Merghoub1, Jedd Wolchok1, Liang Deng1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Antigen presenting cells | Dendritic cell | Checkpoint blockade | Vaccine | T cell | Tumor antigens


DNA-based cancer vaccines designed by SynCon® technology break tolerance in genetically diverse pre-clinical models

Bradley Garman1, Elizabeth K Duperret2, Bernadette Ferraro1, Jewell N Walters1, Kimberly A Kraynyak1, Emma Masteller1, Jian Yan1, Amir S Khan1, David B Weiner2, Laurent M Humeau1

1Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USA 2The Wistar Institute, Philadelphia, PA, USA

Tumor antigens | T cell | Vaccine | Immune tolerance


Gp96-Ig/Costimulator Combination Vaccine Improves T cell Priming, Enhances Immunity, Memory, and Tumor Elimination

Louis Gonzalez1, Louise Giffin1, Jason Rose1, George Fromm1, Suresh De Silva1, Taylor Schreiber1, Jeff Hutchins1

1Heat Biologics, Durham, NC, USA

T cell | Vaccine | Immune adjuvant


Optimization of antigenic composition of a dendritic-cell targeting MIP3α-antigen vaccine and the efficacy of additional IL-10 neutralization therapy in the B16F10 mouse melanoma model.

James Gordy1, Richard Markham1

1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Dendritic cell | Tumor antigens | Vaccine | Chemokine | Inflammation | Tumor microenvironment


Streamlining approaches for the selection of T cell neo-epitopes: from mutanome to therapeutic personalized cancer vaccine

Guilhem Richard1, Leonard Moise1,2, Matthew Ardito1, Frances Terry1, Gad Berdugo3, William Martin1, Anne De Groot1,2

1EpiVax Inc., Providence, RI, USA 2University of Rhode Island, Providence, RI, USA 3EpiVax Oncology LLC, Providence, RI, USA

Vaccine | Regulatory T cell (Treg) | Bioinformatics | Immune tolerance | Neoantigens | Systems biology | T cell | Tumor antigens


Phase 1 dose escalation trial of CV301

Julius Strauss1, Jaydira Del Rivero1, Ravi A. Madan1, Jennifer Marte1, Alanvin Orpia2, Eva Wagner3, Cesar Pico Navarro4, Christopher Heery4, Jeffrey Schlom1, James Gulley1

1Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 2Leidos Biomedical Research, Inc., Bethesda, MD, USA 3Bavarian Nordic, Martinsried, Germany 4Bavarian Nordic, Morrisville, NC, USA

Vaccine | Tumor antigens | Costimulation | Dendritic cell | Clinical study | T cell | Clinical trial | Immune tolerance | Solid tumors | Immune contexture


N-terminally extended proline residues influences the HLA class I antigen processing and decreases CTL responses.

Ayumi Hongo1, Takayuki Kanaseki1, Serina Tokita1, Vitaly Kochin1, Toshihiko Torigoe1

1Sapporo Medical University, Sapporo, Japan

Antigen presenting cells | Targeted therapy | Tumor antigens | T cell | Immune contexture | Neoantigens | Vaccine


A novel oncolytic virus expressing multiple immune regulatory factors to change tumor immune microenvironment and to cause lasting complete tumor eradication in animal models

WILLIAM JIA1, JUN Ding2, Erica Lee2, Dmitry Chouljenko2, Guoyu Liu2, Yanal Murad2, Will Liu2, Zahid Delwar1, Xuexian Bu1

1University of British Columbia, Vancouver, BC, Canada 2Virogin Biotech Ltd, Vancouver, BC, Canada

Tumor microenvironment | Cytokine


In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration

Grammatiki Fotaki1, Chuan Jin1, Di Yu1, Magnus Essand1, Alex Karlsson-Parra1

1Institution of Immunologi, Genetics and Pathology, 751 85 Uppsala, Sweden

Neoantigens | Chemokine | Cytokine | Immune adjuvant | NK/NK T cell | Solid tumors | Vaccine | Dendritic cell | Tumor microenvironment


Immunogenicity of Human Papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCCa)

Charu Aggarwal1, Roger Cohen1, Matthew Morrow2, Kimberly Kraynyak2, Dawson Knoblock2, Joshua Bauml1, Gregory Weinstein1, Jian Yan2, Jean Boyer3, Drishty Mangrolia2, Sandra Oyola2, Susan Duff2, David Weiner4, Ildiko Csiki2, Mark Bagarazzi2

1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA 2Inovio Pharmaceuticals, Plymouth Meeting, PA, USA 3Inovio Pharmaceuticals, San Diego, CA, USA 4Wistar Institute, Philadelphia, PA, USA

Immune tolerance | Checkpoint blockade | Immune suppression | T cell | Tumor evasion | Vaccine | Clinical trial


Cancer immunotherapy with novel vaccine nanodiscs for efficient elimination of mucosal tumors

Rui Kuai1, Yao Xu1, Anna Schwendeman1, James Moon1

1University of Michigan, Ann Arbor, MI, USA

Vaccine | Tumor infiltrating lymphocytes (TILs) | Tumor antigens | Antigen presenting cells | Dendritic cell | Tumor microenvironment


Transduction of MAGE-A1, A3, A4, A10 and IL-12 by ZVex®, a dendritic cell targeting platform induces robust multi-antigen T-cell immune responses without antigenic interference or immunodominance

Tina C. Albershardt1, Anshika Bajaj1, Jardin Leleux1, Tsai-Yu Lin1, Rebecca S. Reeves1, Lisa Y. Ngo1, Ryan White1, Jordan E. Krull1, Reice D. James1, Jan ter Meulen1, Peter Berglund1

1Immune Design, Seattle, WA, USA

Antigen presenting cells | Dendritic cell | Cytokine | Tumor antigens | T cell | Vaccine


PD-L1-specific T cells can be activated by interferon-y and have an anti-tumor effect

Mia Thorup Lundsager1, Mads Hald Andersen2

1Center for Cancer Immune Therapy, Herlev Hospital, Denmark 1IO Biotech ApS, Copenhagen, Denmark, 2Center for Cancer Immune Therapy, Herlev Hospital, Denmark,2IO Biotech ApS, Copenhagen, Denmark

Tumor antigens | Vaccine | T cell


Distinct patterns of clonotypic T cell responses in metastatic castration-resistant prostate cancer pts treated with standard sipuleucel-T (sip-T) compared with pts receiving a booster treatment

Li Zhang1, Harini Kandadi2, Alan Paciorek1, Tao He3, Nadeem Sheikh2, Lawrence Fong1

1University of California San Francisco, San Francisco, CA, USA 2Dendreon Pharmaceuticals Inc., Seattle, WA, USA 3College of Science and Engineering, San Francisco State University, San Francisco, CA, USA

T cell | Vaccine | Solid tumors


In situ vaccination with Flt3L, radiation, and poly-ICLC induces a potent immune response in patients with follicular lymphoma.

Thomas Marron1, Linda Hammerich1, Miriam Merad1, Adeeb Rahman1, Tibor Keler2, Thomas Davis2, Andres Salazar3, Nina Bhardwaj1, Joshua Brody1

1Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Celldex Inc, Hampton, NJ, USA 3Oncovir, Inc, Washington, DC, USA

Dendritic cell | TLR | Tumor microenvironment | Immune monitoring | Clinical study | Biomarkers | Checkpoint blockade | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Vaccine


Contrasting roles of cyclooxygenase-1 and cyclooxygenase-2 in cell-mediated immunity to Listeria monocytogenes

Courtney McDougal1, Erin Theisen1, John-Demian Sauer1

1University of Wisconsin - Madison, Madison, WI, USA

T cell | Antigen presenting cells | Inflammation | Monocyte/Macrophage | Dendritic cell | Vaccine


Overexpression of androgen receptor (AR) in prostate cancer cells following androgen deprivation increases recognition by AR-specific CD8+ T cells

Melissa Gamat1, Brian Olson1, Joseph Seliski1, Thomas Sawicki1, Justin Jeffery1, Leigh Ellis2, Charles Drake3, Jamey Weichert1, Douglas McNeel1

1University of Wisconsin, Madison, WI, USA 2Dana Farber Cancer Institute, Boston, MA, USA 3Columbia University, New York, NY, USA

Tumor antigens | T cell | Vaccine


A heterologous prime-boost vaccination strategy combining a Listeria and DNA-based vaccine encoding prostatic acid phosphatase (PAP) elicits a strong antigen-specific, anti-tumor response

Laura Johnson1, Dirk Brockstedt2, Bill Hanson2, Meredith Leong2, Peter Lauer2, Douglas McNeel1

1University of Wisconsin, Madison, WI, USA 2Aduro Biotech, Berkeley, CA, USA

Tumor antigens | Vaccine


Preclinical in vivo model validation for the development of a novel vaccine based strategy targeting IDO1

Souvik Dey1, Erika Sutanto-Ward1, Arpita Mondal1, Katharina Luise Maria Kopp2, Mai-Britt Zocca2, Ayako Wakatsuki Pedersen2, Mads Hald Andersen3, Alexander J. Muller1

1Lankenau Institute for Medical Research, Wynnewood, PA, USA 2IO Biotech ApS, Copenhagen, Denmark 3University of Copenhagen, Copenhagen, Denmark

Immune tolerance | Inflammation | Tumor evasion | Vaccine | T cell | Immune suppression | Tumor antigens | Tumor microenvironment | Metabolism | Checkpoint blockade


PEGylated tumor membrane nano-vesicles for eliciting adaptive immune responses against melanoma

Lukasz Ochyl1, James Moon1

1University of Michigan, Ann Arbor, MI, USA

Immune adjuvant | TLR | Tumor antigens | T cell | Vaccine


Dendritic cell vaccination combined with chemotherapy for advanced or relapsed head and neck cancer patients induces immunological and clinical responses

Shuichi Ota1

1Sapporo Hokuyu Hospital, Sapporo, Japan

Dendritic cell | TLR | Clinical study | MDSC | Vaccine | Antigen presenting cells | Clinical trial | Solid tumors


Immune mechanisms of the response to TG4010, a viral-based vaccine, in patients with advanced non-small cell lung carcinoma

Kaidre Bendjama1, Eric Quemeneur1, Bérangère Bastien1, Maud Brandely-Talbot1

1Transgene S.A., Illkirch-Graffenstaden, France

Biomarkers | Clinical study | Immune monitoring | Immune contexture | T cell | Tumor antigens | Vaccine


Tumor-specific CD8 T cell checkpoint expressions in melanoma patients that received adenovirally-engineered DC vaccine +/- IFN-α

Patricia M Santos1, Lisa H Butterfield1, Samuel Du1, John M Kirkwood1

1University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA

Antigen presenting cells | Dendritic cell | Clinical trial | Tumor antigens | Checkpoint blockade | Immune monitoring | Vaccine | T cell


A viral vectored vaccine based on shared tumor neoantigens for prevention and treatment of MicroSatellite Instable (MSI) cancers​

Guido Leoni1, Anna Morena D'Alise1, Gabriella Cotugno1, Federica Mori1, Maria Teresa Catanese1, Francesca Langone1, Imma Fichera1, Maria De Lucia2, Rosa Vitale1, Adriano Leuzzi1, Elena Di Matteo1, Antonella Folgori1, Stefano Colloca1, Alfredo Nicosia1,2, Armin Lahm1, Elisa Scarselli1

1Nouscom srl, Rome, Italy 2University of Naples Federico II, Naples, Italy

Bioinformatics | Neoantigens | Tumor antigens | Vaccine


NKTR-214 enhances anti-tumor T cell immune responses induced by checkpoint blockade or vaccination

Meenu Sharma1, Faisal Fa’ak1, Louise Janssen1, Hiep Khong1, Zhilan Xiao1, Yared Hailemichael1, Manisha Singh1, Christina Vianden1, Adi Diab1, Jonathan Zalevsky2, Ute Hoch2, Willem Overwijk1

1UT MD Anderson Cancer Center, Houston, TX, USA 2Nektar Therapeutics, San Francisco, CA, USA

Checkpoint blockade | Vaccine | T cell


A Multi-center Study of hTERT Immunotherapy in Adults with Solid Tumors at High Risk of Relapse Post-standard Therapy

Anthony F. Shields1, Autumn J. McRee2, Jennifer M. Johnson3, Weijing Sun4, Ashish Chintakuntlawar5, Albert J. Sylvester6, Naseem Prostak6, Kimberly A. Kraynyak6, Matthew P. Morrow6, Jeffrey M. Skolnik6, Robert H. Vonderheide7

1Karmanos Cancer Institute, Detroit, MI, USA 2University of North Carolina, Chapel Hill, NC, USA 3Thomas Jefferson University, Philadelphia, PA, USA 4University of Pittsburgh, Pittsburgh, PA, USA 5Mayo Clinic, Rochester, MN, USA 6Inovio Pharmaceuticals, Plymouth Meeting, PA, USA 7Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

Clinical study | Tumor antigens | Clinical trial | Vaccine | Solid tumors


In situ immunocytokine vaccination, radiation and checkpoint blockade therapy prevents engraftment of brain metastases in a murine melanoma model

Raghava Sriramaneni1, Paul A. Clark1, Clinton Heinze1, Emily I. Guy1, Jasdeep Kler2, Sara Busche3, Jonathan A. Lubin2, Peter M. Carlson2, Alexander L. Rakhmilevich2, Stephen D. Gillies4, Hans Loibner5, Alan J. Korman6, Paul M. Sondel2, John S. Kuo2, Zachary S. Morris2

1University of Wisconsin, Madison, WI, USA 2UW Madison, Madison, WI, USA 3UM Madison, Madison, WI, USA 4UW Madison, Carlisle, MA, USA 5UW Madison, Vienna, Austria 6UW Madison, Redwood City, CA, USA

Vaccine | Radiotherapy | Cytokine | Antibody | Checkpoint blockade | Surgery | Immune tolerance